George A. Scangos, Ph.D., is the chief executive officer and a member of the Board of Directors of VIR. Previously, he was the chief executive officer and a member of the board of directors of Biogen since July 2010. From 1996 to July 2010, Dr. Scangos served as the president and chief executive officer of Exelixis, Inc., a drug discovery and development company, where he continues to serve on the board. From 1993 to 1996, Dr. Scangos served as president of Bayer Biotechnology, where he was responsible for research, business development, process development, manufacturing, engineering and quality assurance of Bayer’s biological products. Before joining Bayer in 1987, Dr. Scangos was a professor of biology at Johns Hopkins University, where he is still an adjunct professor. Dr. Scangos served as non-executive chairman of Anadys Pharmaceuticals, Inc., a biopharmaceutical company, from 2005 to July 2010 and was a director of the company from 2003 to July 2010. He currently serves on the Boards of Directors of Agilent, Exelixis, and Decibel Therapeutics.
Dr. Scangos served as the Chair of PhRMA from March of 2016 to January of 2017. He also served as the chair of the California Healthcare Institute in 2010 and was a member of the board of the Global Alliance for TB Drug Development until 2010. He is a member of the boards of trustees of the Boston Museum of Science and the Biomedical Science Careers Program, and a member of the National Board of Visitors of the University of California, Davis School of Medicine.